These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3718913)

  • 1. Ocular toxicity of Anandron in patients treated for prostatic cancer.
    Harnois C; Malenfant M; Dupont A; Labrie F
    Br J Ophthalmol; 1986 Jun; 70(6):471-3. PubMed ID: 3718913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
    Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
    Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report.
    Gomez JL; Dupont A; Cusan L; Tremblay M; Tremblay M; Labrie F
    Am J Med; 1992 May; 92(5):563-6. PubMed ID: 1580304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
    Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
    J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The antiandrogen treatment of patients with prostatic cancer and bone metastases].
    Matveev BP; Bukharkin BV; Zhumagazin ZhD
    Urol Nefrol (Mosk); 1993; (1):10-4. PubMed ID: 7941115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fatal fulminant hepatitis induced by nilutamide (Anandron)].
    Pescatore P; Hammel P; Durand F; Bertheau P; Bernuau J; Huc D; Gerbal JL; Degott C; Benhamou JP
    Gastroenterol Clin Biol; 1993; 17(6-7):499-501. PubMed ID: 8243938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
    Schröder FH
    Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and clinical studies of the antiandrogen Anandron.
    Moguilewsky M; Bertagna C; Hucher M
    J Steroid Biochem; 1987; 27(4-6):871-5. PubMed ID: 3320565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
    Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
    Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilutamide: an antiandrogen for the treatment of prostate cancer.
    Dole EJ; Holdsworth MT
    Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anandron (RU 23908) associated with orchiectomy in stage D prostate cancer. Preliminary results of a randomized, double-blind study.
    Namer M; Amiel J; Toubol J
    Am J Clin Oncol; 1988; 11 Suppl 2():S191-6. PubMed ID: 3071952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R; Pahalajani G; Agarwal A; Zippe C
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular toxicity of anandron.
    Brisset JM; Bertagna C; Proulx L
    Br J Ophthalmol; 1987 Aug; 71(8):639-40. PubMed ID: 3651380
    [No Abstract]   [Full Text] [Related]  

  • 15. Design of antiandrogens and their mechanisms of action: a case study (anandron).
    Raynaud JP; Fiet J; Le Goff JM; Martin PM; Moguilewsky M; Ojasoo T
    Horm Res; 1987; 28(2-4):230-41. PubMed ID: 3331376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
    Barthélémy Y; Colombel M; Gasman D; Patard JJ; Chopin D; Abbou CC
    Prog Urol; 1996 Feb; 6(1):93-7. PubMed ID: 8624534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flutamide photosensitivity.
    Leroy D; Dompmartin A; Szczurko C
    Photodermatol Photoimmunol Photomed; 1996 Oct; 12(5):216-8. PubMed ID: 9112281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect.
    Bennett CL; Raisch DW; Sartor O
    Ann Intern Med; 2002 Oct; 137(7):625. PubMed ID: 12353966
    [No Abstract]   [Full Text] [Related]  

  • 19. Total androgen ablation: American experience.
    Crawford ED; Nabors WL
    Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.